{"organizations": [], "uuid": "44c1bc33ca8b7986502ab38d41582195ab144306", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-gilead-sciences-says-fda-approves/brief-gilead-sciences-says-fda-approves-biktarvy-for-treatment-of-hiv-1-infection-idUSASM000J22", "country": "US", "domain_rank": 408, "title": "BRIEF-Gilead Sciences Says FDA Approves Biktarvy For Treatment Of HIV-1 Infection", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T21:27:00.000+02:00", "replies_count": 0, "uuid": "44c1bc33ca8b7986502ab38d41582195ab144306"}, "author": "", "url": "https://www.reuters.com/article/brief-gilead-sciences-says-fda-approves/brief-gilead-sciences-says-fda-approves-biktarvy-for-treatment-of-hiv-1-infection-idUSASM000J22", "ord_in_thread": 0, "title": "BRIEF-Gilead Sciences Says FDA Approves Biktarvy For Treatment Of HIV-1 Infection", "locations": [], "entities": {"persons": [{"name": "biktarvy", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "hiv-1 infection reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "gilead sciences inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gilead", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 7, 2018 / 7:28 PM / in 15 minutes BRIEF-Gilead Sciences Says FDA Approves Biktarvy For Treatment Of HIV-1 Infection Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Gilead Sciences Inc: \n* U.S. FOOD AND DRUG ADMINISTRATION APPROVES GILEAD’S BIKTARVY® (BICTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE) FOR TREATMENT OF HIV-1 INFECTION \n* GILEAD SCIENCES INC - BIKTARVY HAS A BOXED WARNING IN ITS PRODUCT LABEL REGARDING RISK OF POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B \n* GILEAD SCIENCES - ‍ADDITIONAL CLINICAL TRIALS OF BIKTARVY ONGOING, INCLUDING A DEDICATED STUDY IN WOMEN; PLANS TO PRESENT DATA FROM STUDIES IN 2018​ \n* GILEAD SCIENCES - APPROVAL OF BIKTARVY SUPPORTED BY DATA FROM 4 ONGOING PHASE 3 STUDIES INCLUDING STUDIES 1489 & 1490 IN TREATMENT-NAÏVE HIV-1 INFECTED ADULTS \n* GILEAD SCIENCES - APPROVAL OF BIKTARVY SUPPORTED BY DATA FROM 4 ONGOING PHASE 3 STUDIES INCLUDING STUDIES 1844 & 1878 IN VIROLOGICALLY SUPPRESSED ADULTS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-07T21:27:00.000+02:00", "crawled": "2018-02-07T21:55:17.003+02:00", "highlightTitle": ""}